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High glucose and fatty acid levels impair pancreatic beta cell function. We have recently shown that
palmitate-induced loss of INS-1E insulinoma cells is related to increased reactive oxygen species (ROS)
production as both toxic effects are prevented by palmitoleate. Here we show that palmitate-induced
ROS are mostly mitochondrial: oxidation of MitoSOX, a mitochondria-targeted superoxide probe, is in-
creased by palmitate, whilst oxidation of the equivalent non-targeted probe is unaffected. Moreover,
mitochondrial respiratory inhibition with antimycin A stimulates palmitate-induced MitoSOX oxidation.
We also show that palmitate does not change the level of mitochondrial uncoupling protein-2 (UCP2)
and that UCP2 knockdown does not affect palmitate-induced MitoSOX oxidation. Palmitoleate does not
inﬂuence MitoSOX oxidation in INS-1E cells 7UCP2 and largely prevents the palmitate-induced effects.
Importantly, UCP2 knockdown ampliﬁes the preventive effect of palmitoleate on palmitate-induced ROS.
Consistently, viability effects of palmitate and palmitoleate are similar between cells 7UCP2, but UCP2
knockdown signiﬁcantly augments the palmitoleate protection against palmitate-induced cell loss at
high glucose. We conclude that UCP2 neither mediates palmitate-induced mitochondrial ROS generation
and the associated cell loss, nor protects against these deleterious effects. Instead, UCP2 dampens pal-
mitoleate protection against palmitate toxicity.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
High levels of circulating glucose and non-esteriﬁed fatty acids
(NEFAs) impair pancreatic beta cell function and thus contribute to
the pathogenesis of Type 2 diabetes [1]. We have recently shown
in INS-1E insulinoma cells that mitochondrial dysfunction is in-
volved in this beta cell glucolipotoxicity [2]. Speciﬁcally, overnight
palmitate exposure at high glucose causes oxidative phosphor-
ylation defects that are related to impaired glucose-stimulated
insulin secretion. Concomitantly, palmitate exposure leads to in-
creased reactive oxygen species (ROS) that are associated with cellB.V. This is an open access article
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(C. Affourtit).loss. In agreement with the notion that unsaturated NEFAs provide
protection against the harmful effects of saturated NEFAs [3] the
deleterious effects of palmitate on ROS and INS-1E cell viability are
largely prevented by its monounsaturated counterpart palmitole-
ate [2]. Oxidative stress has been linked extensively to beta cell
dysfunction and death that give rise to Type 2 diabetes [4–7]. In-
deed, ROS scavenging has been reported to improve beta cell
health under glucolipotoxic conditions [8,9]. Beta cells generate
ROS in the cytoplasm through activity of a plasma-membrane-
bound NADPH oxidase and in mitochondria as a consequence of
nutrient catabolism [7]. The origin of the recently reported pal-
mitate-induced ROS in INS-1E cells [2] is unclear at present as is
the mechanism underlying the protective effect of palmitoleate.
ROS are non-canonical signals in glucose-stimulated insulin
secretion (GSIS) [10,11] and studies with isolated islets [12] and
INS-1E cells [13] have revealed that uncoupling protein-2 (UCP2)
attenuates GSIS by dampening ROS production. This acute reg-
ulatory effect of UCP2 on beta cell function is consistent with the
relatively strong GSIS exhibited by the ﬁrst-established Ucp2-ab-
lated mouse strain [14], which suggested a pathological role for
UCP2 in the development of beta cell dysfunction and Typeunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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knockout strain demonstrated that UCP2 restricts the insulin se-
cretory capacity of mice fed a high fat diet [16] and that UCP2
mediates beta cell defects caused by free fatty acids [17]. However,
work on more recently established Ucp2-deﬁcient mouse strains
[18] has suggested a physiological instead of a pathological role for
UCP2 as the protein has been attributed a protective function in
assisting beta cells to deal with sustained oxidative stress [6]. Such
stress is for example encountered after chronic fatty acid exposure
[19,20]. A protective physiological role for UCP2 is consistent with
its reported ROS-dampening effect [13], but predicts that UCP2
activity would ameliorate harmful effects of free fatty acids and
high fat diet rather than mediate them. Evidently, UCP2 involve-
ment in beta cell glucolipotoxicity remains unclear [1].
With the current study we aimed (i) to establish in which
cellular compartment ROS arise in INS-1E cells incubated under
glucolipotoxic conditions and (ii) to clarify if and how UCP2 reg-
ulates ROS production in NEFA-exposed cells. We reveal that pal-
mitate-induced ROS predominantly emerge from mitochondria
and that these ROS correlate strongly with loss of cell viability. We
show that neither palmitate nor palmitoleate signiﬁcantly affect
UCP2 protein level. Consistently, knockdown of UCP2 by RNA in-
terference does not alter palmitate-induced mitochondrial ROS or
associated cell loss. Interestingly, UCP2 knockdown ampliﬁes the
dampening effect of palmitoleate on palmitate-induced ROS and
augments palmitoleate protection against palmitate-provoked cell
loss at high glucose.Experimental
Cell culture
INS-1E insulinoma cells were donated by Prof. Noel Morgan
(University of Exeter Medical School, UK) and maintained in RPMI-
1640 medium (pH 7.4) containing 11 mM glucose, 5% (v/v) fetal
bovine serum (FBS), 10 mM Hepes, 1 mM sodium pyruvate,
50 U/mL penicillin, 50 mg/mL streptomycin, 500 mM β-mercap-
toethanol and 2 mM glutaMAX (Catalogue #35050-061, Life
Technologies). INS-1E cells were seeded at 60,000 cells/well and,
at 70–80% conﬂuence, exposed to NEFAs for 24 h in serum-free
RPMI containing 11 or 4 mM glucose. NEFAs were administered in
conjugation to bovine serum albumin (BSA) as described before [2]
and control cells were exposed to BSA alone. For RNA interference
experiments, INS-1E cells were seeded at 60,000 cells/well, grown
overnight to 50–60% conﬂuence and then transfected with 200 nM
Ucp2-targeted or scrambled (silencer negative control # 1) siRNA
oligonucleotides (both from Ambion, Huntingdon, UK) that were
complexed with 1.67 mg/mL Lipofectamine 2000 (Invitrogen,
Paisley, UK) in serum-free RPMI. After 24-h incubation with
siRNA–lipofectamine complexes, growth medium was replaced
with serum-free RPMI supplemented with either 11 or 4 mM
glucose and with appropriate NEFA:BSA conjugations. Transfected
cells were exposed to NEFAs for 24 h.
ROS
Mitochondrial and cytoplasmic ROS levels were estimated from
MitoSOX (Catalogue #M36008, Life Technologies) or DHE (Cata-
logue #D-1168, Life Technologies) oxidation rates respectively as
described before [13]. Cells seeded, transfected and NEFA-exposed
on 96-well plates were washed into glucose-free Krebs–Ringer–
Hepes (KRH) medium comprising 135 mM NaCl, 3.6 mM KCl,
10 mM Hepes (pH 7.4), 0.5 mM MgCl2, 1.5 mM CaCl2, 0.5 mM
NaH2PO4 and 2 mM L-glutamine, and incubated in this medium
(715 mM antimycin A) for 30 min in a 37 °C air incubator. Next,plates were transferred to a multimode plate reader (PHERAstar
FS, BMG Labtech) and following injection of either 5 mM MitoSOX
or 100 mM DHE, ﬂuorescence was monitored at 28-s intervals for
30 min. Fluorescent MitoSOX and DHE oxidation products were
excited at 510 nm and light emission was detected at 580 nm. The
plate reader's focal height was set at 3.4 mm and its gain was ﬁxed
between different experiments.
Cell number
Densities of attached INS-1E cells were determined by ﬂuor-
escent DAPI-staining. Cells seeded, transfected and NEFA-exposed
on 96-well plates were washed into 200 mL/well PBS, ﬁxed with 4%
(w/v) paraformaldehyde for 20 min at room temperature, and then
incubated with DAPI (0.5 mg/mL in PBS) for another 15 min at
room temperature. To minimise background ﬂuorescence, excess
DAPI was removed by washing 4 with PBS before measuring
total-well ﬂuorescence (λex/em¼358/461 nm) using a multimode
plate reader (PHERAstar FS, BMG Labtech) in bottom-reading and
well-scanning mode. Standard curve-derived cell numbers were
used to quantify NEFA effects on cell viability (Figs. 5 and 6) and to
normalise ROS probe oxidation rates (Figs. 1, 3 and 4).
UCP2 protein
INS-1E cells were seeded in 25-cm2 tissue culture ﬂasks (BD
Bioscience) at 1106 cells/ﬂask and transfected with scrambled or
Ucp2-targeted siRNA at 50–60% conﬂuency. After 24-h incubation,
cells were washed into serum-free RPMI and exposed to NEFA:BSA
conjugations for 24 h. Cells were then removed using a cell scra-
per, washed with ice-cold DPBS and lysed in ice-cold buffer con-
taining 50 mM Tris–HCl (pH 8.0), 1 % (v/v) Nonidet P40, 0.25 % (w/
v) sodium deoxycholate, 0.1% (v/v) SDS, 150 mM NaCl, 1 mM EDTA
and 500 diluted protease inhibitor (#P8340, Sigma-Aldrich).
Following centrifugation of the cell lysates (14,000g for 20 min at
4 °C) protein content of the supernatants was estimated with a
bicinchonic acid assay (Catalogue #23227, Thermo Scientiﬁc) and
aliquots containing 50 mg protein were mixed with ice-cold acet-
one and left overnight at 20 °C. Subsequent centrifugation
(10,000g for 15 min at 4 °C) yielded precipitated protein pellets
that were solubilised and reduced in 20 mL buffer containing 10%
(v/v) glycerol, 50 mM Tris–HCl (pH 6.8), 2% (v/v) SDS, 2% (v/v) β-
mercaptoethanol, 0.1 mM EDTA and 0.01% (w/v) bromophenol
blue. Proteins were separated by SDS-PAGE and transferred to
nitrocellulose membrane (Whatman Protan, BA85) at room tem-
perature using a semi-dry transfer cell (Trans-Blot SD, BIO-RAD)
set at 20 V for 30 min. Rocked (65 rpm) at room temperature,
membranes were blocked for 2 h in TBST [20 mM Tris–HCl
(pH 7.5), 50 mM NaCl and 0.1% (v/v) Tween-20] containing 3% (w/
v) skimmed milk powder (MARVEL). Primary UCP2 antibodies (sc-
6525, Santa Cruz) were then added to the blocking buffer at
0.4 mg/mL. Following overnight incubation at 4 °C (rocked at
100 rpm), membranes were washed 4 over a period of 30 min
with TBST, and then incubated for 2 h at room temperature with
0.2 mg/mL peroxidase-conjugated secondary antibodies. Following
4 TBST washes over a period of 30 min, antibody cross-reactivity
was detected by chemiluminescence (ECL Prime, Amersham) using
a LAS 4000 camera (GE Healthcare) collecting images at 30-s in-
tervals for 5 min. Membrane images were analysed with Im-
ageQuant TL version 7.0 (GE Healthcare). Band intensities were
normalised to total protein per lane by routinely staining mem-
branes with Pierce™ GelCode Blue reagent (Catalogue #24590,
Thermo Scientiﬁc) after UCP2 detection. As described fully in
Fig. 2, UCP2 protein levels were compared between samples by
normalising to partially puriﬁed recombinant human UCP2 stan-
dards donated by Dr. Paul Crichton (MRC Mitochondrial Biology
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Statistical signiﬁcance of mean differences was tested by Stu-
dent’s t-test or ANOVA as speciﬁed in the ﬁgure legends using
GraphPad Prism Version 6.0 for Mac OS X (GraphPad software, San
Diego, CA, USA).Results
Palmitate-induced ROS emerge from mitochondria
INS-1E cells exposed for 24 h to palmitate in the presence of
high glucose exhibit a MitoSOX oxidation rate that is signiﬁcantly
higher than the rate observed in BSA-exposed control cells
(Fig. 1A). This observation agrees with our published results [2]
and strongly suggests that palmitate provokes an increase in mi-
tochondrial ROS as MitoSOX is a widely used mitochondria-tar-
geted superoxide probe [21]. Not all MitoSOX will accumulate in
the mitochondrial matrix, however, and it is thus formally possible
that the data in Fig. 1A reﬂect a palmitate-induced rise in cyto-
plasmic superoxide that is secondary to stimulated NADPH oxi-
dase activity [22,23]. Importantly, DHE is oxidised at the same rate
by palmitate-exposed and BSA control INS-1E cells (Fig. 1B). DHE is
the non-targeted equivalent of MitoSOX and its oxidation is
therefore dominated by cytoplasmic ROS suggesting that, in our
experiments, palmitate has not affected superoxide generation by
NADPH oxidase. In a separate set of experiments, we tested the
effect of mitochondrial respiratory inhibition with antimycin A on
ROS production in INS-1E cells (Fig. 1C). Although the palmitate
effect on the MitoSOX oxidation rate was relatively modest in
these particular experiments (compare Fig. 1C with Figs. 1A and
3A), it is clear that antimycin A signiﬁcantly stimulates MitoSOX
oxidation in both palmitate-exposed and BSA control cells
(Fig. 1C). Antimycin A also increases DHE oxidation a little in BSA
control cells, but not to a statistically signiﬁcant extent. Im-
portantly, antimycin A has no effect on DHE oxidation in palmi-
tate-treated cells (Fig. 1C). Together, the effects of antimycin A
support our assertion that glucolipotoxic ROS emerge from
mitochondria.
Palmitate does not affect UCP2 protein
Next, we explored possible UCP2 involvement in the palmitate-
induced rise in mitochondrial ROS, in the ﬁrst instance by probing
the effect of palmitate and palmitoleate on UCP2 protein level.
Detection and relative quantiﬁcation of UCP2 protein by Western
analysis is complicated by the notorious non-speciﬁcity of com-
mercially available UCP2 antibodies. To conclusively identify bands
that represent UCP2 in INS-1E samples we routinely include par-
tially puriﬁed recombinant human UCP2 protein (hUCP2) and
UCP2-depleted cells in our experiments as positive and negative
controls, respectively. Fig. 2A shows a typical Western blot that
stresses the necessity of these controls: many proteins cross-react
with UCP2 antibodies across the entire molecular weight rangeFig. 1. Palmitate-induced ROS are mitochondrial. Mitochondrial and cytoplasmic
superoxide levels were estimated from MitoSOX (5 mM, panels A and C) and DHE
(100 mM, panels B and C) oxidation rates, respectively, in INS-1E cells exposed for
24 h at 11 mM glucose to BSA-conjugated palmitate or BSA alone. (Panels A and B)
Probes were injected at times indicated by the arrows and background-corrected
ﬂuorescence was recorded at 28-s intervals; for clarity, only a selection of mea-
surements is shown. Relative ﬂuorescence units (RFU) were normalised to cell
number using mean INS-1E viability data (Fig. 5). Probe oxidation rates (inset pa-
nels) were calculated from the slopes of the progress curves; except for the ﬁrst
4 measurements after probe addition, all data were included in these calculations.
Black and grey symbols (both main and inset panels) reﬂect BSA control and pal-
mitate-exposed cells, respectively. Data are mean7SEM from 3–4 independent
exposures that involved 7–8 replicates per treatment. Statistical signiﬁcance of rate
differences was tested by unpaired Student's t-tests. * Differs from the equivalent
palmitate condition (Po0.05). (Panel C) Probe oxidation rates were determined
715 mM antimycin A (striped and white bars, respectively). Data are mean7SEM
from 3–11 independent exposures that involved 7–8 replicates per treatment.
Statistical signiﬁcance of rate differences was tested by two-way ANOVA with Tu-
key's post-hoc analysis. n, nn Differs from the equivalent antimycin A condition
(Po0.05 and Po0.01, respectively).
Fig. 2. UCP2 protein in INS-1E cells is not affected by palmitate and/or palmitoleate. (Panel A) Typical Western blot showing cross-reactivity of UCP2 antibodies with partially
puriﬁed recombinant human UCP2 (Recombinant Ucp2) and INS-1E proteins separated by SDS-PAGE (see Experimental section). Proteins were isolated from cells exposed
for 24 h at 11 mM glucose to BSA-conjugated palmitate (PA) and/or palmitoleate (POA), BSA alone (BSA) or serum-supplemented growth medium (serum). (Panel B) Typical
blots showing data from cells transfected with Ucp2-targeted or scrambled siRNA oligonucleotides (Ucp2 and Scr, respectively) before fatty acid exposure. (Panel C) Typical
relation between signal intensity and amount of recombinant UCP2 as determined for each individual experiment (cf. panels A and B) to allow comparison of UCP2 levels
between different samples. Membrane images were analysed with ImageQuant software using its 1D gel analysis feature: background in deﬁned lanes was subtracted by the
rolling ball function, bands reﬂecting known hUCP2 amounts were boxed, and by applying the quality calibration function the presented relation was generated. (Panel D)
UCP2 content approximated as picograms per 50 mg total extracted protein. Data represent mean7SEM from 3 independent fatty acid exposures. Data were analysed
statistically by one-way ANOVA with Tukey’s post-hoc analysis revealing no signiﬁcant differences between conditions.
Fig. 3. UCP2 knockdown does not change the effect of palmitate on mitochondrial ROS. MitoSOX oxidation rates were determined (see Fig. 1) in non-transfected INS-1E cells
(NT) or cells transfected with scrambled or Ucp2-targeted siRNA oligonucleotides. Cells were exposed for 24 h at 11 or 4 mM glucose (panels A and B, respectively) to BSA-
conjugated palmitate or BSA alone (grey and black bars, respectively). Data represent mean7SEM of 4–11 separate exposures with 3–8 replicates per condition. Statistical
signiﬁcance of rate differences was tested – separately at high and low glucose – by two-way ANOVA with Sidak's post-hoc analysis. nn Differs from the equivalent BSA
condition (P o 0.01).
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grates – only the lower band of this doublet is absent in INS-1E
cells transfected with Ucp2-targeted siRNA (Fig. 2B). As the in-
tensity of this band consistently falls within the linear range of
hUCP2 intensities (Fig. 2C), normalisation to hUCP2 allows relative
quantiﬁcation of UCP2 protein in NEFA-exposed INS-1E cells. Al-
though the absolute values in Fig. 2D bare little relevance given
the impurity of hUCP2 and the possible differential antibody re-
activity with human and rat proteins, it is clear that the level of
UCP2 protein is unchanged in INS-1E cells exposed to palmitate for
24 h at high glucose. Similar exposure to palmitoleate, alone or in
combination with palmitate, tends to lower UCP2 protein moder-
ately, but not to a statistically signiﬁcant extent (Fig. 2D). Equally,
palmitate and/or palmitoleate have no obvious effect on UCP2
levels in INS-1E cells transfected with scrambled siRNA (Fig. 2B).
The relatively stable UCP2 protein level is consistent with our
published observation that mitochondrial proton leak in INS-1E
cells is unaffected by NEFA exposure [2].
UCP2 knockdown ampliﬁes palmitoleate protection against
palmitate-induced ROS
Fig. 2B conﬁrms that the NEFA-sensitivity of UCP2 protein is
similar in non-transfected cells and cells transfected with scram-
bled siRNA, and that transfection with Ucp2-targeted siRNA leads
to UCP2 depletion in both untreated cells and in cells exposed to
BSA-conjugated NEFAs or to BSA alone. Therefore, we used this
RNA interference approach to directly assess UCP2 involvement in
NEFA-induced ROS formation. We measured MitoSOX oxidation in
non-transfected and transfected INS-1E cells exposed to palmitate
for 24 h at 11 and 4 mM glucose (Fig. 3). In line with data shown in
Figs. 1A and C, palmitate exposure causes a signiﬁcant increase in
MitoSOX oxidation in non-transfected cells incubated at high
glucose – importantly, the effect of palmitate is near-identical in
cells transfected with scrambled siRNA (Fig. 3A). MitoSOX oxida-
tion in UCP2-depleted cells exposed to palmitate tends to be
somewhat decreased, but the drop is not statistically signiﬁcant
(Fig. 3A). Palmitate-induced MitoSOX oxidation is relatively mod-
est when cells are exposed at low glucose (Fig. 3B), but again,
palmitate-sensitivity does not depend on the presence of UCP2
(Fig. 3B). These data indicate that UCP2 does not mediate palmi-
tate-induced mitochondrial ROS, and does not protect against
their formation either.
Irrespective of glucose exposure or the presence of UCP2, MitoSOX
oxidation is not affected by palmitoleate (Fig. 4). When administered
in combination with palmitate, palmitoleate dampens the rate ofFig. 4. UCP2 knockdown ampliﬁes attenuation by palmitoleate of palmitate-induced m
transfected INS-1E cells (NT) or cells transfected with scrambled or Ucp2-targeted siRNA
respectively) to BSA-conjugated palmitoleate (white bars), palmitoleate plus palmitate (
exposures with 3–8 replicates per condition. Statistical signiﬁcance of rate differences w
post-hoc analysis. n, nnn Differs from the equivalent Ucp2-targeted condition (Po0.05 apalmitate-induced MitoSOX oxidation at high glucose in non-trans-
fected INS-1E cells from 0.002 to 0.0008 RFU s1 cell1 (Figs. 3A and 4
A, respectively), which is consistent with our previously reported data
[2]. The preventive effect of palmitoleate is similar in cells transfected
with scrambled siRNA (Figs. 3A and 4A). Interestingly, palmitoleate
lowers palmitate-induced MitoSOX even further, to about
0.0003 RFU s1 cell1, in UCP2-depleted cells (Fig. 4A). Generally,
MitoSOX oxidation in BSA-exposed control cells tends to be marginally
higher in cells transfected with scrambled siRNA than in non-trans-
fected or Ucp2-transfected cells (Figs. 3 and 4).
UCP2 knockdown ampliﬁes palmitoleate protection against
palmitate-induced cell loss
Next, we measured viability of non-transfected and transfected
INS-1E cells to probe the effect of UCP2 knockdown on palmitate-
provoked cell loss (cf. [2]). Reﬂecting the effect of transfection on
MitoSOX oxidation, absolute numbers of scrambled-transfected
BSA control cells are lower than their non-transfected and Ucp2-
transfected counterparts (see Fig. 6D), but the relative effects of
NEFAs on cell viability are comparable between scrambled-trans-
fected and non-transfected cells (Fig. 5). Serum withdrawal tends
to have a modest negative effect on the viability of both cell types,
particularly at high glucose (Fig. 5A), as reﬂected by relatively
small drops in the number of BSA-exposed control cells. Interest-
ingly, UCP2 knockdown appears to improve cell resistance against
the lack of serum, although the viability difference between BSA-
exposed cells transfected with scrambled and Ucp2-transfected
siRNA is not statistically signiﬁcant (Fig. 5A). At high and low
glucose (Figs. 5A and B, respectively), palmitate decreases cell
number considerably further, whereas palmitoleate does not exert
any effect in addition to serum withdrawal – UCP2 knockdown
does not change these NEFA responses. Palmitoleate ameliorates
palmitate-induced cell loss, but more strongly at low than high
glucose (Fig. 5). Strikingly, the relatively modest protective effect
of palmitoleate at high glucose is ampliﬁed signiﬁcantly after UCP2
knockdown (Fig. 5A).
Inverse correlation between mitochondrial ROS and cell viability
In line with the suggested causative role of ROS in glucolipo-
toxic beta cell failure [8,9], palmitate affects MitoSOX oxidation
and INS-1E cell number in opposite directions (Figs. 3 and 5, re-
spectively). These palmitate phenotypes are both attenuated by
palmitoleate – a protection that is regulated by UCP2 (Figs. 4 and
5) – suggesting a mechanistic relation between mitochondrial ROSitochondrial ROS. MitoSOX oxidation rates were determined (see Fig. 1) in non-
oligonucleotides. Cells were exposed for 24 h at 11 or 4 mM glucose (panels A and B,
grey bars) or to BSA alone (black bars). Data represent mean7SEM of 3–5 separate
as tested – separately at high and low glucose – by two-way ANOVA with Tukey's
nd Po0.001, respectively).
Fig. 5. Effect of UCP2 knockdown on the viability of NEFA-exposed INS-1E cells. Viability was determined as described in ‘experimental’ using non-transfected cells (black
bars) and cells transfected with scrambled or Ucp2-targeted siRNA oligonucleotides (white and grey bars, respectively). Cells were exposed for 24 h at 11 and 4 mM glucose
(panels A and B, respectively) to BSA-conjugated palmitate and/or palmitoleate, or to BSA alone. Absolute cell numbers (cf. Fig. 6) were expressed as a percentage of control
values obtained with cells grown in standard serum-supplemented growth medium. Values are mean7SEM of 4 independent experiments with 3–5 replicates per
treatment. Statistical signiﬁcance of mean differences was tested – separately at high and low glucose – by two-way ANOVA with Tukey's post-hoc analysis. n, nn, nnn, nnnn
Differs from equivalent palmitate condition (Po0.05, Po0.01, Po0.001, Po0.0001, respectively).
Fig. 6. INS-1E cell viability correlates inversely with mitochondrial ROS. Absolute cell number (cf. Fig. 5) was plotted as a function of the MitoSOX oxidation rate (cf.
Figs. 3 and 4). Data reﬂect the behaviour of non-transfected (NT) cells and that of cells transfected with scrambled or Ucp2-targeted siRNA oligonucleotides after 24-h
exposure at low (G4) and high (G11) glucose to BSA-conjugated palmitate and/or palmitoleate or to BSA alone.
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demonstrates an unequivocal inverse correlation between abso-
lute cell numbers and speciﬁc MitoSOX oxidation rates (Fig. 6). The
relation between cell number and mitochondrial ROS is not linear
as cell loss starts to tail off from a MitoSOX oxidation rate just
below 0.001 RFU s1 cell1 (Fig. 6A). A correlative analysis of our
data illustrates persuasively that palmitate is indeed toxic to INS-
1E cells and that this toxicity is completely prevented by palmi-
toleate (Fig. 6B). The inverse correlation between cell number and
MitoSOX oxidation appears independent of the applied glucose
level (Fig. 6C), suggesting that the glucose permissibility on pal-
mitate toxicity is rather weak (Fig. 6B and C). The inverse corre-
lation between cell number and MitoSOX oxidation is the same in
non-transfected cells as in cells transfected with scrambled or
Ucp2-targeted siRNA (Fig. 6D), which suggests that the relatively
low number of scrambled-transfected cells is owed to comparably
high mitochondrial ROS.Discussion
In this paper we show that palmitate-induced ROS in INS-1E
cells have a mitochondrial origin (Fig. 1) and that cell viability
exhibits a strong inverse correlation with these mitochondrial ROS
(Fig. 6). Moreover, we demonstrate that UCP2 is not needed for the
palmitate effects on mitochondrial ROS or INS-1E cell viability, but
does not ameliorate such effects either (Figs. 3 and 5, respectively).
Importantly, we reveal a new and unexpected phenotype as UCP2
appears to attenuate palmitoleate protection against palmitate
toxicity (Figs. 4 and 5).
Palmitate induces mitochondrial ROS
Palmitate increases the oxidation of hydroethidine by INS-1E
cells, but only when this superoxide probe is targeted to mi-
tochondria through conjugation to a triphenylphosphonium moi-
ety (Fig. 1A). Palmitate-induced oxidation of the targeted hydro-
ethidine (MitoSOX) is further increased following inhibition of
mitochondrial respiration with antimycin A (Fig. 1C). Together,
these data indicate that palmitate triggers formation of mi-
tochondrial superoxide in INS-1E cells. A mitochondrial origin of
palmitate-induced ROS seems at odds with glucolipotoxicity-pro-
voked expression and activity of a cytoplasmic superoxide-gen-
erating NADPH oxidase [24]. Such activity, however, is expected to
increase DHE oxidation, which in our experiments appears un-
affected by palmitate (Fig. 1B). Superoxide formation by NADPH
oxidase is also expected to increase cytoplasmic oxygen uptake –
in our hands, palmitate does not change such non-mitochondrial
respiration in INS-1E cells [2]. Although the likely nature of pal-
mitate-induced ROS is superoxide, it should be kept in mind that
hydroethidine probes are also oxidised, albeit to a lesser extent, by
hydrogen peroxide (in the presence of peroxidases) and in-
tracellular oxidoreductases [21]. Additionally, MitoSOX accumula-
tion into the mitochondrial matrix is dependent on mitochondrial
membrane potential so changes in MitoSOX oxidation may arise
from differential probe availability. As discussed before [13],
however, this eventuality is unlikely given the saturating MitoSOX
concentration we applied in our experiments. Related, it is con-
ceivable that MitoSOX oxidation is limited by multiple drug re-
sistance (MDR) that could lower net uptake of ﬂuorescent dyes by
INS-1E cells. We exposed transfected and non-transfected INS-1E
cells to palmitate in the presence of verapamil – an MDR inhibitor
[25] – to exclude MDR-related limitations. Under all conditions,
verapamil stimulated MitoSOX oxidation modestly, but not to a
statistically signiﬁcant extent (data not shown) – verapamil did
not inﬂuence NEFA or UCP2 phenotypes.Physiological role of UCP2
The ﬁrst evidence for a beta cell UCP2 emerged some time ago
[26] but the physiological role of UCP2 in pancreatic beta cells has
still not been established unequivocally [27]. Indeed, the exact
molecular role of UCP2 remains subject of debate as this carrier
has recently been shown to export carbon compounds from the
mitochondrial matrix [28]. Such a function clearly differs from the
widely assumed uncoupling activity of UCP2 that would result in
partial dissipation of the mitochondrial protonmotive force [29]. In
light of the unclear molecular and physiological roles, it is perhaps
not surprising that UCP2 involvement in glucolipotoxicity remains
contentious [1]. Several functional UCP2 models have been pro-
posed, which include roles in beta cell pathology and consequent
development of Type 2 diabetes [15], and in protecting beta cells
against oxidative stress [6]. These fundamentally different roles
suggest opposite UCP2 involvement in glucolipotoxicity: the pa-
thological model predicts UCP2 is required for palmitate-provoked
ROS formation, whereas the protective model predicts UCP2 pre-
vents such formation instead. Our ﬁndings do not provide support
for either model as UCP2 knockdown does not decrease or in-
crease palmitate-induced mitochondrial ROS production sig-
niﬁcantly (Fig. 3). Although caution is due when inferring phy-
siological meaning from insulinoma cell data, our results would
suggest UCP2 does not mediate harmful effects of palmitate in
beta cells and does not protect against such effects either. Con-
sistently, palmitate does not change the level of UCP2 protein
(Fig. 2). This lack of effect is discrepant with literature that sug-
gests UCP2 expression is relatively high in palmitate-exposed in-
sulinoma cells as well as in islets from mouse models of Type
2 diabetes and lipotoxicity (reviewed in [30]), and in islets of Type
2 diabetic patients [31]. The discrepancy likely arises from the
relative difﬁculty of quantifying UCP2 protein: (i) measuring
mRNA level is insufﬁcient as UCP2 expression is strongly con-
trolled by translation [32] (ii) detecting protein in pancreatic islets
is confounded by the presence of UCP2 in both beta and other islet
cell types [33] and (iii) Western analysis is complicated by the
notorious non-speciﬁcity of commercial UCP2 antibodies (Fig. 2A
and B). We used positive and negative protein controls to un-
equivocally identify UCP2 protein in homogenous INS-1E cell ly-
sates, and quantiﬁed relative protein amount in NEFA-exposed
cells by normalising antibody cross-reactivity to partially puriﬁed
recombinant human UCP2 protein (Fig. 2). Although primary beta
cells may respond differently, we are conﬁdent that UCP2 protein
in INS-1E cells is not affected by overnight palmitate exposure at
high glucose.
UCP2 regulates palmitoleate protection
Palmitoleate protects INS-1E cells against mitochondrial ROS
formation and the associated loss of cells (Fig. 6B). Interestingly,
UCP2 knockdown ampliﬁes the protective effect of palmitoleate
against palmitate-induced ROS (Fig. 4) and cell loss (Fig. 5). These
observations suggest an unexpected role for UCP2 in the regula-
tion of beta cell protection by unsaturated NEFAs against cyto-
toxicity. It has been well established that unsaturated fatty acids
protect beta cells against the toxic effects of their saturated
counterparts [3] but mechanistic understanding of this phenom-
enon is incomplete [34]. Interestingly, cytoprotection is not re-
stricted to lipotoxic stress as unsaturated NEFAs also prevent cell
loss after serum withdrawal or cytokine exposure [35]. In this
respect, it is worth notice that UCP2 knockdown protects against
the moderate viability loss of control INS-1E cells that were de-
prived from serum and exposed overnight to BSA alone at high
glucose (Fig. 5A). Although our data do not explain how UCP2
activity may dampen palmitoleate protection, they ﬁrmly
J. Barlow et al. / Redox Biology 4 (2015) 14–22 21implicate mitochondrial energy metabolism in this poorly under-
stood process.
Glucose dependence of palmitate toxicity
NEFA-induced beta cell defects are often – but not always [35] –
exclusively observed at a high glucose level, which is why such
defects are generally referred to as glucolipotoxicity [36]. Indeed,
our previously published experiments showed statistically insig-
niﬁcant effects of palmitate on MitoSOX oxidation and INS-1E cell
viability when administered overnight at low glucose [2]. Al-
though the effect on MitoSOX oxidation remains insigniﬁcant in
the current experiments, palmitate consistently tends to increase
mitochondrial ROS in non-transfected and transfected cells fol-
lowing exposure at low glucose (Fig. 3B), albeit to a lesser extent
than at high glucose (Fig. 3A). Consistently, palmitate causes sig-
niﬁcant cell loss in non-transfected and transfected cells at both
high and low glucose (Fig. 5). Quantitative differences with our
previously reported cell numbers [2] likely arise from application
of different cell viability assays, but the glucose dependence of the
palmitate viability phenotype appears weak irrespective of such
experimental differences. Indeed, our combined analysis of mi-
tochondrial ROS and INS-1E cell viability data conﬁrms that pal-
mitate is most toxic at high glucose, but causes signiﬁcant damage
at low glucose too (Figs. 6B and C).
Final remarks
In conclusion, our results support the notion that oxidative
stress contributes to pancreatic beta cell glucolipotoxicity and
shed important new light on the elusive mechanism by which
unsaturated NEFAs protect against the harmful effects of their
saturated counterparts. In addition, our ﬁndings inform ongoing
debate on the physiological role of the beta cell UCP2.Acknowledgements
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